Published population pharmacokinetic models of valproic acid in adult patients: a systematic review and external validation in a Chinese sample of inpatients with bipolar disorder

References

• Merikangas KR, Jin R, He JP, et al. Prevalence and correlates of bipolar spectrum disorder in the world mental health survey initiative. Arch Gen Psychiatry. 2011;68(3):241–251. https://doi.org/10.1001/archgenpsychiatry.2011.12
   Google Scholar
• Hibar DP, Westlye LT, van Erp TG, et al. Subcortical volumetric abnormalities in bipolar disorder. Mol Psychiatry. 2016;21(12):1710–1716. https://doi.org/10.1038/mp.2015.227
   Google Scholar
• McIntyre RS, Berk M, Brietzke E, et al. Bipolar disorders. Lancet. 2020;396(10265):1841–1856. https://doi.org/10.1016/S0140-6736(20)31544-0
   Google Scholar
• Yatham LN, Kennedy SH, Parikh SV, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disord. 2018;20(2):97–170. https://doi.org/10.1111/bdi.12609
   Google Scholar
• Johannessen CU, Johannessen SI. Valproate: past, present, and future. CNS Drug Rev. 2003;9(2):199–216.
   Google Scholar
• Vossler DG, Weingarten M, Gidal BE. Summary of antiepileptic drugs available in the United States of America: working toward a world without epilepsy. Epilepsy Curr. 2018;18(4 Suppl 1):1–26.
   Google Scholar
• Atmaca M. Valproate and neuroprotective effects for bipolar disorder. Int Rev Psychiatry. 2009;21(4):410–413.
   Google Scholar
• Dutta S, Reed RC. Distinct absorption characteristics of oral formulations of valproic acid/divalproex available in the United States. Epilepsy Res. 2007;73(3):275–283.
   Google Scholar
• Methaneethorn J. A systematic review of population pharmacokinetics of valproic acid. Br J Clin Pharmacol. 2018;84(5):816–834. https://doi.org/10.1111/bcp.13510 .
   Google Scholar
• Silva MF, Aires CC, Luis PB, et al. Valproic acid metabolism and its effects on mitochondrial fatty acid oxidation: a review. J Inherit Metab Dis. 2008;31(2):205–216. https://doi.org/10.1007/s10545-008-0841-x
   Google Scholar
• Ghodke-Puranik Y, Thorn CF, Lamba JK, et al. Valproic acid pathway: pharmacokinetics and pharmacodynamics. Pharmacogenet Genomics. 2013;23(4): 236–241. https://doi.org/10.1097/FPC.0b013e32835ea0b2 .
   Google Scholar
• Perucca E. Clinically relevant drug interactions with antiepileptic drugs. Br J Clin Pharmacol. 2006;61(3):246–255. https://doi.org/10.1111/j.1365-2125.2005.02529.x .
   Google Scholar
• Hiemke C, Bergemann N, Clement HW, et al. Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017. Pharmacopsychiatry. 2018;51(1–02): 9–62. https://doi.org/10.1055/s-0043-116492 .
   Google Scholar
• Fleming J, Chetty M. Therapeutic monitoring of valproate in psychiatry: how far have we progressed? Clin Neuropharmacol. 2006;29(6):350–360.
   Google Scholar
• Gidal B, Spencer N, Maly M, et al. Valproate-mediated disturbances of hemostasis: relationship to dose and plasma concentration. Neurology. 1994;44(8):1418–1422. https://doi.org/10.1212/WNL.44.8.1418
   Google Scholar
• Patsalos PN, Spencer EP, Berry DJ. Therapeutic drug monitoring of antiepileptic drugs in epilepsy: a 2018 update. Ther Drug Monit. 2018;40(5):526–548.
   Google Scholar
• Mould DR, Upton RN. Basic concepts in population modeling, simulation, and model-based drug development. CPT Pharmacometrics Syst Pharmacol. 2012;1(9):e6.
   Google Scholar
• Mould DR, Upton RN. Basic concepts in population modeling, simulation, and model-based drug development-part 2: introduction to pharmacokinetic modeling methods. CPT Pharmacometrics Syst Pharmacol. 2013;2(4):e38.
   Google Scholar
• Upton RN, Mould DR. Basic concepts in population modeling, simulation, and model-based drug development: part 3-introduction to pharmacodynamic modeling methods. CPT Pharmacometrics Syst Pharmacol. 2014;3(1):e88.
   Google Scholar
• El DE, Meinshausen J, Buhl K, et al. Generation of pharmacokinetic data during routine therapeutic drug monitoring: Bayesian approach vs. pharmacokinetic studies. Ther Drug Monit. 1993;15(4):281–288. https://doi.org/10.1097/00007691-199308000-00004
   Google Scholar
• Proost JH. Adaptive control of drug dosage regimens using maximum a posteriori probability Bayesian fitting. Int J Clin Pharmacol Ther. 1995;33(10):531–536.
   Google Scholar
• Zhao CY, Jiao Z, Mao JJ, et al. External evaluation of published population pharmacokinetic models of tacrolimus in adult renal transplant recipients. Br J Clin Pharmacol. 2016;81(5):891–907. https://doi.org/10.1111/bcp.12830 .
   Google Scholar
• Yukawa E, To H, Ohdo S, et al. Population-based investigation of valproic acid relative clearance using nonlinear mixed effects modeling: influence of drug-drug interaction and patient characteristics. J Clin Pharmacol. 1997;37(12):1160–1167.
   Google Scholar
• Tanikawa K, Matsumoto Y, Matsumoto M, et al. Population pharmacokinetic parameters of valproic acid; conventional and slow release formulation. Jap J Clin Pharmacol Therapeut. 1998;29(3):489–494. https://doi.org/10.3999/jscpt.29.489
   Google Scholar
• Blanco-Serrano B, Otero MJ, Santos-Buelga D, et al. Population estimation of valproic acid clearance in adult patients using routine clinical pharmacokinetic data. Biopharm Drug Dispos. 1999;20(5):233–240.
   Google Scholar
• Yukawa E, Nonaka T, Yukawa M, et al. Pharmacoepidemiologic investigation of a clonazepam-valproic acid interaction by mixed effect modeling using routine clinical pharmacokinetic data in Japanese patients. J Clin Pharm Ther. 2003;28(6):497–504.
   Google Scholar
• Jankovic SM, Milovanovic JR. Pharmacokinetic modeling of valproate from clinical data in Serbian epileptic patients. Methods Find Exp Clin Pharmacol. 2007;29(10):673–679.
   Google Scholar
• Vucićević K, Miljković B, Pokrajac M, et al. The influence of drug-drug interaction and patients’ characteristics on valproic acid’s clearance in adults with epilepsy using nonlinear mixed effects modeling. Eur J Pharm Sci. 2009;38(5):512–518.
   Google Scholar
• Jankovic SM, Milovanovic JR, Jankovic S. Factors influencing valproate pharmacokinetics in children and adults. Int J Clin Pharmacol Ther. 2010;48(11):767–775.
   Google Scholar
• Ogusu N, Saruwatari J, Nakashima H, et al. Impact of the superoxide dismutase 2 Val16Ala polymorphism on the relationship between valproic acid exposure and elevation of γ-glutamyltransferase in patients with epilepsy: a population pharmacokinetic-pharmacodynamic analysis. PLoS One. 2014;9(11):e111066. https://doi.org/10.1371/journal.pone.0111066
   Google Scholar
• Lin WW, Jiao Z, Wang CL, et al. Population pharmacokinetics of valproic acid in adult Chinese epileptic patients and its application in an individualized dosage regimen. Ther Drug Monit. 2015;37(1) 76–83. https://doi.org/10.1097/FTD.0000000000000100 .
   Google Scholar
• Alqahtani S, Alandas N, Alsultan A. Estimation of apparent clearance of valproic acid in adult Saudi patients. Int J Clin Pharm. 2019;41(4):1056–1061.
   Google Scholar
• Botha JH, Gray AL, Miller R. A model for estimating individualized valproate clearance values in children. J Clin Pharmacol. 1995;35(10):1020–1024.
   Google Scholar
• Yukawa E. A feasibility study of the multiple-peak approach for pharmacokinetic screening: population-based investigation of valproic acid relative clearance using routine clinical pharmacokinetic data. J Pharm Pharmacol. 1995;47(12A):1048–1052.
   Google Scholar
• Yukawa E, Honda T, Ohdo S, et al. Detection of carbamazepine-induced changes in valproic acid relative clearance in man by simple pharmacokinetic screening. J Pharm Pharmacol. 1997;49(8):751–756.
   Google Scholar
• Serrano BB, García SM, Otero MJ, et al. Valproate population pharmacokinetics in children. J Clin Pharm Ther. 1999;24(1):73–80.
   Google Scholar
• Park HM, Kang SS, Lee YB, et al. Population pharmacokinetics of intravenous valproic acid in Korean patients. J Clin Pharm Ther. 2002;27(6):419–425. https://doi.org/10.1046/j.1365-2710.2002.00440.x
   Google Scholar
• EL DE, Fuseau E, DAS EL, et al. Pharmacokinetic modelling of valproic acid from routine clinical data in Egyptian epileptic patients. Eur J Clin Pharmacol. 2004;59(11):783–790.
   Google Scholar
• Jiang DC, Wang L. Population pharmacokinetic model of valproate and prediction of valproate serum concentrations in children with epilepsy. Acta Pharmacol Sin. 2004;25(12):1576–1583.
   Google Scholar
• Jiang DC, Wang L, Wang YQ, et al. Population pharmacokinetics of valproate in Chinese children with epilepsy. Acta Pharmacol Sin. 2007;28(10):1677–1684.
   Google Scholar
• Dutta S, Faught E, Limdi NA. Valproate protein binding following rapid intravenous administration of high doses of valproic acid in patients with epilepsy. J Clin Pharm Ther. 2007;32(4):365–371.
   Google Scholar
• Correa T, Rodríguez I, Romano S. Population pharmacokinetics of valproate in Mexican children with epilepsy. Biopharm Drug Dispos. 2008;29(9):511–520.
   Google Scholar
• Goto S, Seo T, Hagiwara T, et al. Potential relationships between transaminase abnormality and valproic acid clearance or serum carnitine concentrations in Japanese epileptic patients. J Pharm Pharmacol. 2008;60(2):267–272. https://doi.org/10.1211/jpp.60.2.0017
   Google Scholar
• Ueshima S, Aiba T, Makita T, et al. Characterization of non-linear relationship between total and unbound serum concentrations of valproic acid in epileptic children. J Clin Pharm Ther. 2008;33(1):31–38. https://doi.org/10.1111/j.1365-2710.2008.00885.x
   Google Scholar
• Jiang D, Bai X, Zhang Q, et al. Effects of CYP2C19 and CYP2C9 genotypes on pharmacokinetic variability of valproic acid in Chinese epileptic patients: nonlinear mixed-effect modeling. Eur J Clin Pharmacol. 2009;65(12):1187–1193. https://doi.org/10.1007/s00228-009-0712-x
   Google Scholar
• Williams JH, Jayaraman B, Swoboda KJ, et al. Population pharmacokinetics of valproic acid in pediatric patients with epilepsy: considerations for dosing spinal muscular atrophy patients. J Clin Pharmacol. 2012;52(11):1676–1688.
   Google Scholar
• Ding J, Wang Y, Lin W, et al. A population pharmacokinetic model of valproic acid in pediatric patients with epilepsy: a non-linear pharmacokinetic model based on protein-binding saturation. Clin Pharmacokinet. 2015;54(3):305–317. https://doi.org/10.1007/s40262-014-0212-8
   Google Scholar
• Nakashima H, Oniki K, Nishimura M, et al. Determination of the optimal concentration of valproic acid in patients with epilepsy: a population pharmacokinetic-pharmacodynamic analysis. PLoS One. 2015;10(10):e141266. https://doi.org/10.1371/journal.pone.0141266
   Google Scholar
• Mei S, Feng W, Zhu L, et al. Effect of CYP2C19, UGT1A8, and UGT2B7 on valproic acid clearance in children with epilepsy: a population pharmacokinetic model. Eur J Clin Pharmacol. 2018;74(8):1029–1036. https://doi.org/10.1007/s00228-018-2440-6
   Google Scholar
• Rodrigues C, Chhun S, Chiron C, et al. A population pharmacokinetic model taking into account protein binding for the sustained-release granule formulation of valproic acid in children with epilepsy. Eur J Clin Pharmacol. 2018;74(6):793–803. https://doi.org/10.1007/s00228-018-2444-2
   Google Scholar
• Xu S, Chen Y, Zhao M, et al. Population pharmacokinetics of valproic acid in epileptic children: effects of clinical and genetic factors. Eur J Pharm Sci. 2018;122:170–178.
   Google Scholar
• Guo J, Huo Y, Li F, et al. Impact of gender, albumin, and CYP2C19 polymorphisms on valproic acid in Chinese patients: a population pharmacokinetic model. J Int Med Res. 2020;48(8):1220751833. https://doi.org/10.1177/0300060520952281
   Google Scholar
• Gu X, Zhu M, Sheng C, et al. Population pharmacokinetics of unbound valproic acid in pediatric epilepsy patients in China: a protein binding model. Eur J Clin Pharmacol. 2021;77(7):999–1009. https://doi.org/10.1007/s00228-020-03080-y
   Google Scholar
• Birnbaum AK, Ahn JE, Brundage RC, et al. Population pharmacokinetics of valproic acid concentrations in elderly nursing home residents. Ther Drug Monit. 2007;29(5):571–575.
   Google Scholar
• Methaneethorn J. Population pharmacokinetics of valproic acid in patients with mania: implication for individualized dosing regimens. Clin Ther. 2017;39(6):1171–1181. https://doi.org/10.1016/j.clinthera.2017.04.005 .
   Google Scholar
• Methaneethorn J, Leelakanok N. Predictive ability of published population pharmacokinetic models of valproic acid in Thai manic patients. J Clin Pharm Ther. 2021;46(1):198–207. https://doi.org/10.1111/jcpt.13280 .
   Google Scholar
• Ibarra M, Vázquez M, Fagiolino P, et al. Sex related differences on valproic acid pharmacokinetics after oral single dose. J Pharmacokinet Pharmacodyn. 2013;40(4):479–486.
   Google Scholar
• Jamsen KM, McLeay SC, Barras MA, et al. Reporting a population pharmacokinetic-pharmacodynamic study: a journal’s perspective. Clin Pharmacokinet. 2014;53(2):111–122.
   Google Scholar
• Kanji S, Hayes M, Ling A, et al. Reporting guidelines for clinical pharmacokinetic studies: the ClinPK statement. Clin Pharmacokinet. 2015;54(7):783–795. https://doi.org/10.1007/s40262-015-0236-8
   Google Scholar
• Chen Y-T, Wang C-Y, Yin Y-W, et al. Population pharmacokinetics of oxcarbazepine: a systematic review. Expert Rev Clin Pharmacol. 2021;14(7):853–864. https://doi.org/10.1080/17512433.2021.1917377
   Google Scholar
• Zhao M, Li G, Qiu F, et al. Development and validation of a simple and rapid UPLC-MS assay for valproic acid and its comparison with immunoassay and HPLC methods. Ther Drug Monit. 2016;38(2):246–252.
   Google Scholar
• Bergstrand M, Hooker AC, Wallin JE, et al. Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS J. 2011;13(2):143–151.
   Google Scholar
• Comets E, Brendel K, Mentre F. Computing normalised prediction distribution errors to evaluate nonlinear mixed-effect models: the npde add-on package for R. Comput Methods Programs Biomed. 2008;90(2):154–166.
   Google Scholar
• Marsot A, Michel F, Chasseloup E, et al. Phenobarbital in intensive care unit pediatric population: predictive performances of population pharmacokinetic model. Fundam Clin Pharmacol. 2017;31(5):558–566.
   Google Scholar
• Cloyd JC, Fischer JH, Kriel RL, et al. Valproic acid pharmacokinetics in children. IV. Effects of age and antiepileptic drugs on protein binding and intrinsic clearance. Clin Pharmacol Ther. 1993;53(1):22–29.
   Google Scholar
• Tauzin M, Treluyer JM, Nabbout R, et al. Simulations of valproate doses based on an external evaluation of pediatric population pharmacokinetic models. J Clin Pharmacol. 2019;59(3):406–417. https://doi.org/10.1002/jcph.1333
   Google Scholar
• Kim JY, Cheong HS, Park BL, et al. Comprehensive variant screening of the UGT gene family. Yonsei Med J. 2014;55(1):232–239. https://doi.org/10.3349/ymj.2014.55.1.232
   Google Scholar
• Fricke-Galindo I, Cespedes-Garro C, Rodrigues-Soares F, et al. Interethnic variation of CYP2C19 alleles, ‘predicted’ phenotypes and ‘measured’ metabolic phenotypes across world populations. Pharmacogenomics J. 2016;16(2):113–123. https://doi.org/10.1038/tpj.2015.70
   Google Scholar
• Garcia-Martin E, Martinez C, Ladero JM, et al. Interethnic and intraethnic variability of CYP2C8 and CYP2C9 polymorphisms in healthy individuals. Mol Diagn Ther. 2006;10(1):29–40.
   Google Scholar
• Dorji PW, Wangchuk S, Boonprasert K, et al. Pharmacogenetic relevant polymorphisms of CYP2C9, CYP2C19, CYP2D6, and CYP3A5 in Bhutanese population. Drug Metab Pers Ther. 2019;34(4): https://doi.org/10.1515/dmpt-2019-0020
   Google Scholar
• Du Z, Jiao Y, Shi L. Association of UGT2B7 and UGT1A4 Polymorphisms with serum concentration of antiepileptic drugs in children. Med Sci Monit. 2016;22:4107–4113.
   Google Scholar
• Sun YX, Zhuo WY, Lin H, et al. The influence of UGT2B7 genotype on valproic acid pharmacokinetics in Chinese epilepsy patients. Epilepsy Res. 2015;114:78–80.
   Google Scholar
• Wang P, Lin XQ, Cai WK, et al. Effect of UGT2B7 genotypes on plasma concentration of valproic acid: a meta-analysis. Eur J Clin Pharmacol. 2018;74(4):433–442. https://doi.org/10.1007/s00228-017-2395-z
   Google Scholar
• Passey C, Birnbaum AK, Brundage RC, et al. Dosing equation for tacrolimus using genetic variants and clinical factors. Br J Clin Pharmacol. 2011;72(6):948–957.
   Google Scholar
• Cai X, Li R, Sheng C, et al. Systematic external evaluation of published population pharmacokinetic models for tacrolimus in adult liver transplant recipients. Eur J Pharm Sci. 2020;145:105237.
   Google Scholar
• Mizuno T, Emoto C, Fukuda T, et al. Model-based precision dosing of sirolimus in pediatric patients with vascular anomalies. Eur J Pharm Sci. 2017;109S:S124–S131.
   Google Scholar
• Sheiner LB, Beal SL. Bayesian individualization of pharmacokinetics: simple implementation and comparison with non-Bayesian methods. J Pharm Sci. 1982;71(12):1344–1348.
   Google Scholar
• Karlsson MO, Savic RM. Diagnosing model diagnostics. Clin Pharmacol Ther. 2007;82(1):17–20.
   Google Scholar
• Kodama Y, Koike Y, Kimoto H, et al. Binding parameters of valproic acid to serum protein in healthy adults at steady state. Ther Drug Monit. 1992;14(1):55–60. https://doi.org/10.1097/00007691-199202000-00009
   Google Scholar
• Franconi F, Brunelleschi S, Steardo L, et al. Gender differences in drug responses. Pharmacol Res. 2007;55(2):81–95.
   Google Scholar
• Zaccara G, Perucca E. Interactions between antiepileptic drugs, and between antiepileptic drugs and other drugs. Epileptic Disord. 2014;16(4):409–431.
   Google Scholar
• Tsiropoulos I, Gichangi A, Andersen M, et al. Trends in utilization of antiepileptic drugs in Denmark. Acta Neurol Scand. 2006;113(6):405–411.
   Google Scholar
• Malerba A, Ciampa C, De Fazio S, et al. Patterns of prescription of antiepileptic drugs in patients with refractory epilepsy at tertiary referral centres in Italy. Epilepsy Res. 2010;91(2–3):273–282. https://doi.org/10.1016/j.eplepsyres.2010.08.002
   Google Scholar
• Spina E, Pisani F, de Leon J. Clinically significant pharmacokinetic drug interactions of antiepileptic drugs with new antidepressants and new antipsychotics. Pharmacol Res. 2016;106:72–86. https://doi.org/10.1016/j.phrs.2016.02.014.
   Google Scholar
• Sovner R, Davis JM. A potential drug interaction between fluoxetine and valproic acid. J Clin Psychopharmacol. 1991;11(6):389.
   Google Scholar
• Cruz-Flores S, Hayat GR, Mirza W. Valproic toxicity with fluoxetine therapy. Mo Med. 1995;92(6):296–297.
   Google Scholar
• Lucena MI, Blanco E, Corrales MA, et al. Interaction of fluoxetine and valproic acid. Am J Psychiatry. 1998;155(4):575.
   Google Scholar
• de Leon J, Santoro V, D’Arrigo C, et al. Interactions between antiepileptics and second-generation antipsychotics. Expert Opin Drug Metab Toxicol. 2012;8(3):311–334.
   Google Scholar
• Italiano D, Spina E, de Leon J. Pharmacokinetic and pharmacodynamic interactions between antiepileptics and antidepressants. Expert Opin Drug Metab Toxicol. 2014;10(11):1457–1489.
   Google Scholar
• Wade JR, Kelman AW, Howie CA, et al. Effect of misspecification of the absorption process on subsequent parameter estimation in population analysis. J Pharmacokinet Biopharm. 1993;21(2):209–222. https://doi.org/10.1007/BF01059771
   Google Scholar
• US FDA. Guidance for industry: population pharmacokinetics [online]. cited 18 Sep 2014. Available from: http://www.fda.gov/downloads/Drugs/Guidances/UCM072137.pdf
   Google Scholar
• Stockmann C, Hersh AL, Roberts JK, et al. Predictive performance of a vancomycin population pharmacokinetic model in neonates. Infect Dis Ther. 2015;4(2):187–198. https://doi.org/10.1007/s40121-015-0067-9
   Google Scholar
• Methaneethorn J, Lohitnavy M. External evaluation of a published population pharmacokinetic model of valproic acid in Thai manic patients. Eur J Hosp Pharm. 2020;27(3):168–172. https://doi.org/10.1136/ejhpharm-2018-001653 .
   Google Scholar
• Jackson J, McCollum B, Ognibene J, et al. Three patients needing high doses of valproic Acid to get therapeutic concentrations. Case Rep Psychiatry. 2015;2015:542862.
   Google Scholar
• Iannaccone T, Sellitto C, Manzo V, et al. Pharmacogenetics of carbamazepine and valproate: focus on polymorphisms of drug metabolizing enzymes and transporters. Pharmaceuticals (Basel). 2021;14(3):204. https://doi.org/10.3390/ph14030204
   Google Scholar
• Dasgupta A. Usefulness of monitoring free (unbound) concentrations of therapeutic drugs in patient management. Clin Chim Acta. 2007;377(1–2):1–13.
   Google Scholar
• Wu X, Li H, Dong W, et al. Determination of free valproic acid concentration in 569 clinical samples by LC-MS/MS after hollow fiber centrifugal ultrafiltration treatment. Ther Drug Monit. 2021;43(6):789–796. https://doi.org/10.1097/FTD.0000000000000903
   Google Scholar
• Patsalos PN, Berry DJ, Bourgeois BF, et al. Antiepileptic drugs – best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring ILAE commission on therapeutic strategies. Epilepsia. 2008;49(7):1239–1276. https://doi.org/10.1111/j.1528-1167.2008.01561.x
   Google Scholar
• Sandson NB, Marcucci C, Bourke DL, et al. An interaction between aspirin and valproate: the relevance of plasma protein displacement drug–drug interactions. Am J Psychiatry. 2006;163(11):1891–1896. https://doi.org/10.1176/ajp.2006.163.11.1891
   Google Scholar
• Ruan CJ, de Leon J. Thirty years of both ignorance and clinical experience suggest that clozapine intoxication during co-occurring infections and inflammation may have higher morbidity and mortality than is currently believed. Psychosomatics. 2019;60(2):221–222.
   Google Scholar
• de Leon J. The effects of antiepileptic inducers in neuropsychopharmacology, a neglected issue. Part I: a summary of the current state for clinicians. Rev Psiquiatr Salud Ment. 2015;8(2):97–115.
   Google Scholar
• de Leon J, The effects of antiepileptic inducers in neuropsychopharmacology, a neglected issue. Part II: Pharmacological issues and further understanding. Rev Psiquiatr Salud Ment. 2015;8(3):167–188.
   Google Scholar
• Cerveny L, Svecova L, Anzenbacherova E, et al. Valproic acid induces CYP3A4 and MDR1 gene expression by activation of constitutive androstane receptor and pregnane X receptor pathways. Drug Metab Dispos. 2007;35(7):1032–1041. https://doi.org/10.1124/dmd.106.014456
   Google Scholar
• Vrzal R, Doricakova A, Novotna A, et al. Valproic acid augments vitamin D receptor-mediated induction of CYP24 by vitamin D3: a possible cause of valproic acid-induced osteomalacia? Toxicol Lett. 2011;200(3):146–153. https://doi.org/10.1016/j.toxlet.2010.11.008
   Google Scholar
• de Jong FA, van der Bol JM, Mathijssen RH, et al. Irinotecan chemotherapy during valproic acid treatment: pharmacokinetic interaction and hepatotoxicity. Cancer Biol Ther. 2007;6(9):1368–1374. https://doi.org/10.4161/cbt.6.9.4567
   Google Scholar
• Citrome L, Josiassen R, Bark N, et al. Pharmacokinetics of aripiprazole and concomitant lithium and valproate. J Clin Pharmacol. 2005;45(1):89–93. https://doi.org/10.1177/0091270004269870
   Google Scholar
• Diaz FJ, Santoro V, Spina E, et al. Estimating the size of the effects of co-medications on plasma clozapine concentrations using a model that controls for clozapine doses and confounding variables. Pharmacopsychiatry. 2008;41(3):81–91. https://doi.org/10.1055/s-2007-1004591
   Google Scholar
• Diaz FJ, Eap CB, Ansermot N, et al. Can valproic acid be an inducer of clozapine metabolism? Pharmacopsychiatry. 2014;47(3):89–96. https://doi.org/10.1055/s-0034-1371866
   Google Scholar
• Riesselman A, Strobl B, Cooley AT, et al. A case report that suggested that aspirin’s effects on valproic acid metabolism may contribute to valproic acid’s inducer effects on clozapine metabolism. J Clin Psychopharmacol. 2013;33(6):812–814. https://doi.org/10.1097/JCP.0b013e3182a4ea8f
   Google Scholar
• de Leon J. Future studies on the interaction between clozapine and valproic acid should aspire to include longitudinal designs and free valproate concentrations, and should consider that inducer and/or inhibitory effects may vary with time, the individual, and the auto-induction of valproic acid. Ther Drug Monit. 2020;42(1):159–161.
   Google Scholar
• Spina E, D’Arrigo C, Santoro V, et al. Effect of valproate on olanzapine plasma concentrations in patients with bipolar or schizoaffective disorder. Ther Drug Monit. 2009;31(6):758–763. https://doi.org/10.1097/FTD.0b013e3181c0590e
   Google Scholar
• Haslemo T, Olsen K, Lunde H, et al. Valproic acid significantly lowers serum concentrations of olanzapine - an interaction effect comparable with smoking. Ther Drug Monit. 2012;34(5):512–517. https://doi.org/10.1097/FTD.0b013e3182693d2a
   Google Scholar
• Tveito M, Smith RL, Høiseth G, et al. The effect of valproic acid on olanzapine serum concentration: a study including 2791 patients treated with olanzapine tablets or long-acting injections. J Clin Psychopharmacol. 2019;39(6):561–566. https://doi.org/10.1097/JCP.0000000000001126
   Google Scholar
• Zang YN, Dong F, Li AN, et al. The impact of smoking, sex, infection, and comedication administration on oral olanzapine: a population pharmacokinetic model in Chinese psychiatric patients. Eur J Drug Metab Pharmacokinet. 2021;46(3):353–371. https://doi.org/10.1007/s13318-021-00673-5
   Google Scholar
• Fisher JE, Nau H, Löscher W. Alterations in the renal excretion of valproate and its metabolites after chronic treatment. Epilepsia. 1991;32(1):146–150.
   Google Scholar
• McLaughlin DB, Andrews JA, Hooper WD, et al. Apparent autoinduction of valproate beta-oxidation in humans. Br J Clin Pharmacol. 2000;49(5):409–415. https://doi.org/10.1046/j.1365-2125.2000.00191.x
   Google Scholar
• Lana F, Martí-Bonany J, de Leon J. Ibuprofen may increase pharmacological action of valproate by displacing it from plasma proteins: a case report. Am J Psychiatry. 2016;173(9):941–942.
   Google Scholar
• Lana F, Martí-Bonany J, Fuster J, et al. Reduction in serum concentration of valproic acid secondary to the intake of ibuprofen as an example of valproic acid auto-induction metabolism. Actas Esp Psiquiatr. 2016;44(4):136–144.
   Google Scholar
• Bennett S, Shad MU. Valproic acid autoinduction: a case-based review. Int J Bipolar Disord. 2021;9(1):27.
   Google Scholar
• de Leon J. Personalizing dosing of risperidone, paliperidone and clozapine using therapeutic drug monitoring and pharmacogenetics. Neuropharmacology. 2020;168:107656.
   Google Scholar
• de Leon J, Schoretsanitis G, Smith RL, et al. An international adult guideline for making clozapine titration safer by using 6 ancestry-based personalized dosing titrations, CRP and clozapine levels. Pharmacopsychiatry. 2021;55(2):73–86. https://doi.org/10.1055/a-1625-6388
   Google Scholar